We report a randomized, double-blind, multicenter trial in which amphotericin B colloidal dispersion (ABCD [Amphotec]; 6 mg/kg/day) was compared with amphotericin B (AmB; 1.0-1.5 mg/kg/day) for the treatment of invasive aspergillosis in 174 patients. For evaluable patients in the ABCD and AmB treatment groups, respective rates of therapeutic response (52% vs. 51%; ), mortality (36% vs. 45%; ), and death P p 1.0 P p .4 due to fungal infection (32% vs. 26%; ) were similar. Renal toxicity was lower (25% vs. 49%; P p .7 P p ) and the median time to onset of nephrotoxicity was longer (301 vs. 22 days; ) in patients treated .002 P ! .001 with ABCD. Rates of drug-related toxicity in patients receiving ABCD and AmB, respectively, were 53% versus 30% (chills), 27% versus 16% (fever), 1% versus 4% (hypoxia) and 22% versus 24% (toxicity requiring study drug discontinuation). ABCD appears to have equivalent efficacy and superior renal safety, compared with AmB, in the treatment of invasive aspergillosis. However, infusion-related chills and fever occurred more frequently in patients receiving ABCD than in those receiving AmB.
Invasive aspergillosis is an increasingly common complication in severely immunocompromised patients, with estimated infection rates of 3%-11% in bone marrow transplant recipients [1, 2] . As a leading cause of both nosocomial pneumonia and death during the first 100 days after bone marrow transplantation [3] , as-pergillosis has an associated mortality rate of 190% if untreated, particularly in patients with CNS involvement and in bone marrow transplant recipients with pulmonary aspergillosis [4] .
Despite advances in new antifungal agents, amphotericin B (AmB) remains the treatment of choice for invasive aspergillosis. However, its effective use may be complicated or limited by potential adverse effects, such as renal impairment (noted in 60%-80% of patients) [5] [6] [7] [8] . Concomitant use of nephrotoxins (e.g., ami-noglycosides, cyclosporine, and/or tacrolimus) in this patient population further compounds the risk for renal toxicity [9] .
Amphotericin B colloidal dispersion (ABCD; Amphotec or Amphocil [InterMune] ) is a high-affinity lipid complex that consists of AmB and sodium cholesteryl sulfate in a near 1:1 molar ratio [10] . The pharmacokinetic profile of the ABCD complex demonstrates reduced renal tissue uptake, compared with conventional AmB therapy, with serum levels similar to those noted with use of AmB [11] . In vitro and in vivo studies have suggested that ABCD and AmB have comparable efficacy against a broad spectrum of pathogenic fungi, albeit at higher daily doses (approximately 3-4 times greater than normal dose values) [12] [13] [14] .
In phase I and II clinical trials, ABCD has been shown to have an excellent renal safety profile, even when it is used to treat patients who have preexisting renal insufficiency or patients who are concomitantly receiving nephrotoxic agents [15] [16] [17] [18] . In 2 comparative trials (1 that involved patients with invasive aspergillosis [19] and 1 that involved patients with febrile neutropenia [20] ), ABCD appeared be associated with a lower incidence of nephrotoxicity and a longer time to onset of nephrotoxicity than did AmB. The efficacy of ABCD has been found to be similar to or better than that of AmB in studies of both aspergillosis and empiric treatment for neutropenic patients with fever [19, 20] . This is the first study to prospectively compare ABCD with AmB for use as first-line therapy for invasive Aspergillus infection in a randomized, double-blind fashion.
PATIENTS AND METHODS

Patient Population
Patients who were eligible for inclusion in the study were 12 age of age and had newly diagnosed, proved, or probable invasive aspergillosis plus у1 of the following underlying conditions: hematologic malignancy, bone marrow transplant, disease requiring immunosuppressive therapy (solid-organ transplant or solid tumors), chronic obstructive pulmonary disease, or other immune-compromising conditions (chronic granulomatous disease, diabetes mellitus, cystic fibrosis, or AIDS). Informed consent was obtained from each patient or from their parent or guardian, and the human experimentation guidelines of the US Department of Health and Human Services and/or those of the authors' institution(s) were followed in the conduct of the present study.
Patients were excluded from the study if any of the following criteria were met: a history of anaphylactoid or other serious, life-threatening reactions to AmB; a life expectancy of !3 days; receipt of systemic antifungal therapy that could not be discontinued; receipt of a cumulative dose of у10 mg of AmB per kg during the 10 days before study entry; evidence of improvement in the Aspergillus infection, as noted on clinical or radiographic examination; presence of grade 4 graft-versus-host disease; or renal dysfunction significant enough to be considered a contraindication to AmB treatment. In addition, among patients in whom the lungs were the sole site of aspergillosis, those who had concurrent pneumonia due to other organisms were excluded from the study. Patients who had undergone surgical resection of the infected tissue were excluded from the study unless the surgeon documented failure to resect the entire infection or there was histopathologic evidence of residual disease at the surgical margins.
Study Design
The present study was a prospective, randomized, double-blind, multicenter trial in which ABCD (6.0 mg/kg/day) was compared with AmB (Fungizone [Bristol-Myers Squib]; 1.0 or 1.5 mg/kg/day) for the treatment of patients with invasive aspergillosis. The dosage of ABCD was increased from 4.0 to 6.0 mg/kg/day, after the enrollment of 4 patients, on the basis of patient toleration of dosages of up to 7.5 mg/kg/day in a phase I study [15] . The dosage of AmB administered at each center ranged from 1.0 to 1.5 mg/kg/day and was left to the discretion of the investigator. All efforts were made to administer the study drug daily; however, patients were allowed to miss 2 doses in any 7-day period. The study drug was infused over a 4-h period, but, if the drug was well tolerated, this infusion period could be decreased to 2 h after administration of 2 doses. Premedication for the prevention of infusion-related adverse events was not permitted on the first day of drug infusion but was used as needed thereafter; the choice of agent was left to the discretion of the investigator.
Patients were stratified, before randomization, into 2 groups on the basis of prognostic indicators. High-risk patients included those who had undergone bone marrow or liver transplantation, those with AIDS, and those with cerebral aspergillosis. Low-risk patients were all other eligible patients. Patients were to receive the assigned treatment until completion of 6 weeks of therapy or until 2 weeks after all signs and symptoms of infection had disappeared (in concert with resolution of neutropenia). Patients who responded to treatment were permitted to continue receiving blinded therapy, if desired.
Aspergillus infection was categorized as either "proved" (a clinical course consistent with invasive aspergillosis, as well as identification of typical hyphal elements or growth of Aspergillus organisms in an invasively obtained specimen from a normally sterile site) or "probable" (infection of the lung only, as defined by clinical and radiographic evidence of invasive pulmonary aspergillosis plus 2 sputum cultures positive for Aspergillus organisms or either a positive culture result or visualization of characteristic hyphal elements on a bronchoalveolar lavage specimen) [21] . Subsequent histopathologic proof of infection in patients with probable aspergillosis resulted in reclassification of the infection as "proved."
Response to therapy was categorized as follows [21] :
1. "Complete response" was defined by the resolution of all signs and symptoms according to clinical, laboratory, and radiographic parameters, as well as the conversion of the fungal culture results from positive to negative, if such results were available.
2. "Partial response" was defined by clinically important improvements in disease activity (including у50% improvement in radiographic findings) or у50% improvement in fungal disease in patients who ultimately died, with the absence of positive results of fungal culture or histopathologic examination on autopsy.
3. "Stable disease" was defined by clinical improvement and !50% improvement in radiographic findings. 4. "Failure" occurred if the patient died of aspergillosis, died of any other cause and did not have an autopsy performed, or had progression of fungal infection.
One author (J.-A.v.B.) reviewed the data under blinded conditions and provided a uniform assessment of patient evaluability, therapeutic response, reason for termination of therapy, cause of death, and association of aspergillosis with death.
Statistical Issues
End points. Therapeutic response, which was composed of a complete response, a partial response, or stable disease, was prospectively identified as the primary efficacy end point of the study. Patients evaluable for efficacy included those with proved or probable aspergillosis who had received study drug for at least 7 days (7 doses) and who had no major protocol violations (e.g., concomitant systemic antifungal therapy). The primary safety variable was renal function, as measured by the change in serial serum creatinine values obtained through day 7.
Secondary efficacy end points included overall mortality as well as death due to fungal infection that occurred by study day 84 [21, 22] . Nephrotoxicity was analyzed as a secondary end point and was defined as either a doubling of the serum creatinine level from its baseline value, a serum creatinine level increase of 1.0 mg/dL, or a у50% decrease in calculated creatinine clearance. "Time to renal toxicity" was defined as the number of days between the first infusion of study drug and the first observation of renal toxicity. For patients who did not experience renal toxicity, censoring used the date that the last creatinine specimen was collected during receipt of study drug.
Results of selected laboratory tests (for determination of creatinine, total bilirubin, aspartate aminotransferase, alkaline phosphatase, and hemoglobin levels and of peripheral WBC and platelet counts) were evaluated at baseline, on study days 8, 15, 22, and 29, and at the end of treatment.
Sample size and study accrual. Approximately 173 patients per treatment group were required to demonstrate equivalence in efficacy between the 2 groups, which was defined as an upper bound of the 95% CI for a difference of not greater than 15% between treatment groups. Detection of a difference between the mean serum creatinine level (‫ע‬SD) noted on study day 8 and that measured at baseline ( mg/dL versus 0.50 ‫ע‬ 0.64 mg/dL, respectively) required a total of 146 patients 0.20 ‫ע‬ 0.64 for 80% power and a 0.05 type 1 error. After 14 years of study, given the difficulty in accrual and the need for data, the study was terminated and analyzed despite failure to meet the efficacy accrual goal.
Statistical analysis. Summary statistics are presented by treatment group, both within each prognosis stratum and across prognosis strata. For nominal categorical data (e.g., race), general association Cochran-Mantel-Haenszel tests that stratified for prognosis stratum were reported; for continuous or ordinal categorical data (e.g., age), the Cochran-Mantel-Haenszel row mean score tests, with stratification for prognosis stratum, were used. For time-to-event data (e.g., time to onset of nephrotoxicity or time to death), Kaplan-Meier product limit estimates were obtained and values were compared by use of the logrank test. Repeated-measure analyses were done for serial laboratory measurements.
RESULTS
Patient population.
From January 1993 through February 1997, a total of 174 patients (88 of whom were taking ABCD and 86 of whom were taking AmB) were randomized and received the study drug at 37 multinational sites: the United States (32 sites), Canada (3), France (1), and the Slovak Republic (1). The median age of the study patients was 48 years (range, 7-81 years) and 44 years (range, 0-81 years) in the ABCD and AmB treatment groups, respectively. Sex was relatively evenly balanced: 51% and 49% were men, respectively. The majority of patients in the ABCD and AmB groups had absolute neutrophil values of у500/mm 3 at baseline (71% vs. 65%, respectively) and had received prior AmB therapy (80% vs. 77%, respectively). The median cumulative dose of prior AmB therapy in each of the 2 treatment groups was 2.0 mg/kg. Hematologic malignancy was the most common underlying disease in both treatment groups (in 75% of the ABCD group and 64% of the AmB group).
Underlying disease and site of infection were similar in the 2 groups, although the proportion of patients with proved or probable aspergillosis (by blinded third-party review) was lower in the ABCD group (85% vs. 94%) (table 1). Also similar were the proportions of patients in the ABCD and AmB treatment groups who were admitted to intensive care unit settings during the study (8 and 10 patients, respectively), who received in- tubation (9 and 13 patients, respectively) or dialysis (1 patient and 1 patient, respectively), and who had graft-versus-host disease (22 and 17 patients, respectively).
Treatment durations were similar in the 2 groups: the median duration of therapy was 13.0 days (range, 1-357 days) for the ABCD group and 14.5 days (range, 1-87 days) for the AmB group. The median cumulative doses of ABCD and AmB were 4684 and 857 mg (range, 4-87,208 mg and 55-6271 mg) or 72 and 14 mg/kg (range, 0.1-1140 mg/kg and 1.0-133 mg/kg), respectively.
Response. All 174 patients who received at least 1 dose of study drug were included in the intent-to-treat (ITT) efficacy analysis. In the evaluable patient efficacy analysis, 71 patients were excluded (38 in the ABCD group and 33 in the AmB group), thus leaving 103 patients. For patients in the ABCD and AmB groups, reasons for exclusion from the analysis included receipt of !7 doses of study medication (28 and 29 patients, respectively), lack of proved or probable aspergillosis (13 and 5 patients, respectively), use of prohibited medication (2 and 3 patients, respectively), or concurrent cytomegalovirus pneumonia (1 patient in the AmB group). Some patients were excluded for 11 reason.
The rate of therapeutic response in evaluable patients was 52% in 50 patients taking ABCD and 51% in 53 patients taking AmB (  ; table 2 ). In the ITT analysis, rates of therapeutic P p .96 response were 35% and 35% in the 2 groups, respectively ( ). Rates of therapeutic response were also similar when P p .5 analyzed by prognostic stratum (table 2) .
When analyzed by patient subset, therapeutic response according to absolute neutrophil count, underlying illness, and site of infection showed no significant differences between treatment groups ( ). Rates of therapeutic response in patients P 1 .05 who had neutropenia at baseline (absolute neutrophil count, !500 cells/mm 3 ) were 51% versus 51% in the ABCD group and the AmB group, respectively; in patients with hematologic malignancy, the rates were 50% versus 52%; and in those with chronic obstructive pulmonary disease, rates were 60% versus 25%. In patients with pulmonary aspergillosis, rates of therapeutic response were 47% versus 58%.
Mortality. In the evaluable patient population, the overall mortality rate was 36% versus 45% in the ABCD and AmB groups, respectively (95% CI, Ϫ10% to 28%). Stratification by prognostic group demonstrated mortality rates of 45% versus 55%, respectively, in the high-risk stratum and 30% versus 39%, respectively, in the low-risk stratum.
In the ITT analysis, mortality rates were similar in the 2 treatment groups: 50% in the ABCD group versus 55% in the AmB group (95% CI, Ϫ10% to 20%). In the high-risk stratum, 66% of patients who took ABCD died, compared with 63% of patients who took AmB. In the low-risk stratum, mortality rates were 40% and 49% in the ABCD and AmB groups, respectively.
The median time to death was 95 days versus 54 days in the ABCD group and the AmB group, respectively, in the analysis of evaluable patients ( ), and 31 days versus 40 days, P p .5 respectively, in patients in the ITT analysis ( ). Because P p .9 of earlier dropouts in the AmB group, review of the proportion of deaths, as determined by Kaplan-Meier estimation, revealed a more marked difference between the ABCD and AmB groups in both the analysis of evaluable patients (39% vs. 78%) and the ITT analysis (60% vs. 73%) than did the aforementioned analysis of absolute deaths.
The rate of death due to fungal infection, as assessed by a blinded reviewer, was similar in the ABCD and AmB groups: 32% versus 26%, respectively, in the evaluable patient analysis ( ) and 40% versus 36%, respectively, in the ITT analysis P p .7 ( ). The Kaplan-Meier estimates of death due to fungal P p .6 infection at day 84 were 35% for both treatment groups in the evaluable population and 52% versus 43% for the ABCD and AmB groups, respectively, in the ITT analysis. No patient deaths were deemed to be related to study drug.
Safety. The study drug was discontinued prematurely because of toxicity in 22% of patients who took ABCD and in 24% of those who took AmB. Sixteen (84.2%) of 19 study drug discontinuations among patients who received ABCD and 21 of 21 study drug discontinuations among patients who received AmB were considered by the investigator to be possibly or probably related to study drug. The most common reason for study drug discontinuation in the AmB group was renal toxicity; 16 patients in the AmB group discontinued therapy for this reason, compared with 3 patients in the ABCD group. The most common treatment-limiting adverse events in the ABCD group were infusion-related toxicities, which caused 8 patients to discontinue therapy, compared with 3 patients in the AmB group.
The baseline serum creatinine level was similar in the 2 groups (see table 3 ) and ranged from 0.3 to 2.9 mg/dL in patients who took ABCD and from 0.3 to 3.0 mg/dL in patients who took AmB. The incidence of nephrotoxicity was almost twice as high in patients treated with AmB, compared with patients who received ABCD: 49% versus 25%;
(table P p .002 3). In addition, renal toxicity occurred earlier during the course of AmB therapy, compared with ABCD therapy (median time to renal toxicity, 22.0 vs. 301.0 days, respectively;
). P ! .001 The mean absolute increase in the serum creatinine level during the study was significantly lower in patients who took ABCD than in those who took AmB, both from baseline to day 8 (0.25 vs. 0.43 mg/dL;
) and from baseline to the end of treat-P p .05 ment (0.4 vs. 0.6 mg/dL; ) (mean percentage change from P p .05 baseline to end of treatment, 31% vs. 76%;
). Hypo-P p .002 kalemia (serum potassium, !3.0 mEq/L) occurred in 17% versus 21% of patients in the 2 groups ( ). P p .5 Drug-related chills (53% vs. 30%;
) and fever (27% P p .002 vs. 16%; ) occurred more frequently in patients who P p .01 took ABCD than in those who took AmB (table 4) . Drugrelated hypoxia, however, occurred less frequently in patients who took ABCD than in those who took AmB (1% vs. 4%; ). Similarly, rates of overall hypoxia that was graded as P p .4 severe, regardless of association with study drug, were lower in patients who received ABCD than in patients who received AmB (2% vs. 6%, respectively).
DISCUSSION
This is the first prospective, double-blind, randomized comparison of antifungal agents used as first-line treatment for immunocompromised patients with invasive aspergillosis. A comparison of ABCD and conventional AmB revealed a similar efficacy. Analysis of the primary safety end point-that is, the change in the serum creatinine level-demonstrated a signifi- Renal toxicity in 174 patients evaluated in a double-blind, multicenter increase of 1.0 mg/dL in serum creatinine, or a у50% decrease in calculated creatinine clearance. c All patients who received у1 dose of study drug were included in these analyses.
cantly lower incidence of increases in the serum creatinine level among patients who received ABCD than among patients who received AmB. The superior renal safety of ABCD was confirmed by the demonstration of a significantly lower incidence of nephrotoxicity in patients who received ABCD (25% vs. 49%; ), with use of a prospectively defined composite term P p .002 for nephrotoxicity [18, 19] . In addition, the median time to onset of nephrotoxicity was significantly longer in patients who received ABCD (301 vs. 22 days;
), and the number of P ! .001 patients who discontinued the study drug because of renal events was lower: 3 patients who took ABCD versus 16 who took AmB. Comparison of the proportion of patients in whom serum creatinine values rose to levels double or greater than those measured at baseline, in keeping with analyses performed in studies elsewhere [23] , also demonstrated a superior renal safety profile of ABCD compared with AmB.
Prospective comparative trials of AmB versus other antifungal agents as initial therapy for patients with invasive aspergillosis have proved difficult to conduct for a number of reasons, including the relative scarcity of Aspergillus infections, compared with other types of infection, at any one medical center; the life-threatening nature of the infection; the perceived high toxicity of AmB; and the large numbers of patients required to document equivalence or superiority. The current study is the largest controlled trial of therapy for invasive aspergillosis to be performed to date. Despite the participation of 37 international sites, however, the study was terminated before its accrual goal was reached, with each site enrolling an average of slightly more than 1 patient per year. Hence, an insufficient number of patients were enrolled to document true equivalence in efficacy between the 2 agents. However, the accrual goal for the primary safety end point of the study, that of the change in the serum creatinine level during the first week of therapy, was met.
The improved renal safety of ABCD, compared with that of AmB, as demonstrated in the present trial, is consistent with findings of studies published elsewhere [19, 20] . In a retrospective, historically controlled comparison of ABCD with AmB as therapy for invasive aspergillosis, renal toxicity occurred in fewer patients who took ABCD (8% vs. 43%, respectively), despite a higher incidence of baseline renal dysfunction (median baseline serum creatinine level, 1.8 vs. 1.0 mg/dL) [19] . Similarly, ABCD incurred significantly lower rates of nephrotoxicity than did AmB in a randomized, blinded study of empiric antifungal therapy in febrile neutropenic patients (20% and 52%, respectively; P ! .001), and the onset of renal toxicity was significantly delayed [20] . Of interest is the similarity in the incidence of nephrotoxicity in patients who received ABCD in the febrile neutropenic study, compared with that in patients in the current study, despite the use of a higher dose of ABCD here: 4 versus 6 mg/kg/day (median cumulative dose, 1884 vs. 4684 mg). Thus, there is no evidence for a dose-response relationship of ABCD with regard to nephrotoxicity.
Rates of acute infusion-related toxicity were higher in patients who received ABCD than in those who received AmB for both chills (53% vs. 30%) and fever (27% vs. 16%). Moreover, 8 patients who took ABCD discontinued therapy because of infusion-related events, compared with 3 patients who took AmB. However, the frequency of drug-related hypoxia was lower in patients who took ABCD than in those who took AmB (1% vs. 4%), as was the frequency of overall hypoxia that was graded as severe (irrespective of apparent relationship to study drug; 2% vs. 6%).
The efficacy of the 2 antifungal agents, as judged by rates of therapeutic response, appeared to be similar in both the evaluable patient analysis (52% vs. 51% in the ABCD vs. AmB groups, respectively) and the ITT analysis (35% vs. 35%). However, the study was underpowered to detect a difference. Also similar were both the overall mortality rates (36% vs. 45%) and the rates of death deemed to be caused by fungal infection (32% vs. 26%) in the 2 groups. The therapeutic response rate in patients who received ABCD in the current study (52%) is similar to that observed in an earlier prospective study that evaluated the use of ABCD as therapy for patients with aspergillosis who had failed to respond or who had exhibited intolerance to AmB (49%) [19] . The response rate was also similar to that observed in a recent randomized European Organization for Research and Treatment of Cancer (EORTC) study that compared 2 dosages of lipid formulations of AmB (1 and 4 mg/kg/day) for the treatment of invasive aspergillosis: 64% of 41 patients and 48% of 46 evaluable patients, respectively [24] . The mortality rates in the EORTC trial were also similar to those in the current study: 59% and 67%, respectively (rate of death due to aspergillosis, 22% and 20%, respectively). True comparison with the EORTC study, however, is complicated by the presence of proven aspergillosis in only 23% of patients enrolled in that trial as well as by the receipt of prior antifungal therapy (mainly AmB) in 195% of evaluable patients.
There are several limitations to the current study that should be considered. Because enrollment occurred over a 4-year period, it is conceivable that changes in underlying disease or an evolution in the standard of care for patients with aspergillosis during that interval may have affected the outcome of the study. The low rate of annual enrollment per study site may have resulted in a center bias. The higher proportion of patients in the AmB group with proved or probable aspergillosis, compared with the proportion of such patients in the ABCD group (94% vs. 85%, respectively), may have conceivably biased the efficacy outcomes. In addition, the heterogeneity of risk factors and underlying diseases in patients with aspergillosis, although seemingly well balanced in the current study, may have affected outcome. Finally, in the current study, as in other studies of immunosuppressed patients with invasive aspergillosis, there was a discrepancy between the evaluable patient population and the population of patients randomized. Exclusions from the evaluable patient population were in large part due to early termination (i.e., before 7 days) in both treatment groups, which reflected the high rates of early death and of complications in this group of patients. Although we attempted to compensate for this discrepancy by performing analyses on both the evaluable and ITT populations, the potential impact of these early terminations on the efficacy and safety end points should be considered.
In conclusion, this randomized controlled trial that compared first-line therapy for invasive aspergillosis in immunocompromised patients suggests that the efficacy associated with conventional AmB therapy is preserved during therapy with ABCD and that renal toxicity is significantly lessened. Infusionrelated toxicities were the most common reason for premature discontinuation in patients treated with ABCD. However, because of a substantially lower rate of discontinuation resulting from renal toxicity in the ABCD group, compared with that in the AmB group, the overall rate of premature study drug discontinuation because of toxicity was similar in the 2 groups. Additional comparative studies are encouraged, to facilitate the optimal use of modern antifungal agents in the treatment of aspergillosis.
